ES2088385T3 - Formulaciones de liposomas con una elevada relacion agente antineoplasico/lipido. - Google Patents

Formulaciones de liposomas con una elevada relacion agente antineoplasico/lipido.

Info

Publication number
ES2088385T3
ES2088385T3 ES88400521T ES88400521T ES2088385T3 ES 2088385 T3 ES2088385 T3 ES 2088385T3 ES 88400521 T ES88400521 T ES 88400521T ES 88400521 T ES88400521 T ES 88400521T ES 2088385 T3 ES2088385 T3 ES 2088385T3
Authority
ES
Spain
Prior art keywords
drug
liposomes
agent
lipid
liposome formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88400521T
Other languages
English (en)
Inventor
Marcel B Bally
Richard S Ginsberg
George N Mitilenes
Pieter R Culis
Lawrence D Mayer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Liposome Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21808094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2088385(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Liposome Co Inc filed Critical Liposome Co Inc
Application granted granted Critical
Publication of ES2088385T3 publication Critical patent/ES2088385T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

LA INVENCION PROPORCIONA UN METODO PARA LA ENCAPSULACION DE AGENTES NEOPLASICOS EN LIPOSOMAS, QUE TIENEN PREFERIBLEMENTE UNA ELEVADA PROPORCION FARMACO/LIPIDO. SE PUEDEN PREPARAR LIPOSOMAS POR UN PROCESO QUE CARGA EL FARMACO POR UN MECANISMO ACTIVO USANDO UN GRADIENTE IONICO TRANSMEMBRANA, Y PREFERIBLEMENTE UN GRADIENTE DE PH TRANSMEMBRANA, USANDO ESTA TECNICA LAS EFICACIAS DE OCLUSION SE APROXIMAN AL 100%, Y SE PUEDE CARGAR LOS LIPOSOMAS CON EL FARMACO INMEDIATAMENTE ANTES DE SU EMPLEO, ELIMINANDO LOS PROBLEMAS DE ESTABILIDAD RELACIONADOS CON LA RETENCION DE FARMACOS EN LOS LIPOSOMAS. LAS RELACIONES FARMACO/LIPIDO EMPLEADAS SON DE 3-80 VECES MAS ALTAS QUE LAS DE PREPARACIONES DE LIPOSOMAS TRADICIONALES Y LA VELOCIDAD DE LIBERACION DEL FARMACO DE LOS LIPOSOMAS ES MENOR. TAMBIEN SE INCLUYE UN METODO PARA DETERMINAR AGENTES ANTINEOPLASICOS LIBRES EN UNA PREPARACION DE LIPOSOMAS.
ES88400521T 1987-03-05 1988-03-04 Formulaciones de liposomas con una elevada relacion agente antineoplasico/lipido. Expired - Lifetime ES2088385T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2215487A 1987-03-05 1987-03-05

Publications (1)

Publication Number Publication Date
ES2088385T3 true ES2088385T3 (es) 1996-08-16

Family

ID=21808094

Family Applications (2)

Application Number Title Priority Date Filing Date
ES88400521T Expired - Lifetime ES2088385T3 (es) 1987-03-05 1988-03-04 Formulaciones de liposomas con una elevada relacion agente antineoplasico/lipido.
ES95117084T Expired - Lifetime ES2198429T3 (es) 1987-03-05 1988-03-04 Vesiculas unilaminares grandes que comprenden fosfolipidos saturados y metodo para su preparacion.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES95117084T Expired - Lifetime ES2198429T3 (es) 1987-03-05 1988-03-04 Vesiculas unilaminares grandes que comprenden fosfolipidos saturados y metodo para su preparacion.

Country Status (17)

Country Link
EP (2) EP0719546B1 (es)
JP (1) JP2882607B2 (es)
KR (1) KR960013703B1 (es)
AT (2) ATE231389T1 (es)
AU (3) AU620545B2 (es)
BR (1) BR1100687A (es)
CA (1) CA1338702C (es)
DE (3) DE3856550T2 (es)
DK (1) DK174869B1 (es)
ES (2) ES2088385T3 (es)
GR (1) GR3020725T3 (es)
HK (1) HK1007500A1 (es)
IE (1) IE75713B1 (es)
IL (1) IL85608A (es)
LU (1) LU90717I2 (es)
NL (1) NL300036I1 (es)
WO (1) WO1988006442A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1323306C (en) * 1987-03-05 1993-10-19 Mircea C. Popescu Pharmacological agent-lipid solution preparation
CA1338702C (en) * 1987-03-05 1996-11-12 Lawrence D. Mayer High drug:lipid formulations of liposomal- antineoplastic agents
US4946683A (en) * 1987-11-18 1990-08-07 Vestar, Inc. Multiple step entrapment/loading procedure for preparing lipophilic drug-containing liposomes
IE63518B1 (en) * 1987-11-18 1995-05-03 Vestar Inc Multiple step entrapment/loading procedure for preparing lipophilic drug-containing liposomes
IL91664A (en) * 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
EP0472639A4 (en) * 1989-05-15 1992-07-01 The Liposome Company, Inc. Accumulation of drugs into liposomes by a proton gradient
US5227170A (en) * 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
EP0412507A1 (de) * 1989-08-08 1991-02-13 Humboldt-Universität zu Berlin Verfahren zur Grössenfraktionierung hochmolekularer Stoffe mit Hilfe von Hohlträgern
DK0555229T3 (da) * 1990-07-31 1996-08-19 Liposome Co Inc Akkumulation af aminosyrer og peptider i liposomer
WO1992004009A1 (en) * 1990-09-10 1992-03-19 School Of Pharmacy, University Of London Liposomes
DE4038075C1 (en) * 1990-11-29 1992-03-19 B. Braun Melsungen Ag, 3508 Melsungen, De Encapsulating solid or liq. lipophilic agents - comprises mixing hydration medium with phospholipid increasing temp. to above soln. phase change temp. and adding remaining medium
EP0661044A1 (en) * 1991-07-03 1995-07-05 NeXstar Pharmaceuticals, Inc. Drug-containing liposomes
EP0546951A1 (en) * 1991-12-13 1993-06-16 The Liposome Company, Inc. Combination of liposome encapsulated antineoplastic agents, such as doxorubicin with colony stimulating factors
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
DE4430592A1 (de) 1994-08-20 1996-02-22 Max Delbrueck Centrum Liposomale Zubereitung, ihre Herstellung und ihre Verwendung
US5858397A (en) * 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
DE19639811A1 (de) * 1996-09-27 1998-04-02 Artur Herzog Dr Mesmer Verwendung einer Liposomenlösung zur Verstärkung der Wirksamkeit und/oder Verminderung der Toxizität von Arzneimitteln
IL130822A (en) * 1996-10-15 2005-12-18 Elan Pharm Inc N-acyl phosphatidylethanolamine-mediated liposomaldrug delivery
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US7030155B2 (en) 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US7351427B2 (en) 1998-06-18 2008-04-01 Busulipo Ab Pharmaceutical composition, a method of preparing it and a method of treatment by use thereof
EP1089727B8 (en) * 1998-06-18 2006-03-08 Hassan, Moustapha, Dr. Liposomal formulations of busulphan
CA2389147A1 (en) * 1999-11-05 2001-05-10 Seed Capital Investment-2 (Sci-2) B.V. Method for the formulation of substances having a low water-solubility and lipophilicity and formulation thus obtained
WO2001082892A2 (de) * 2000-05-02 2001-11-08 Pharmacept Gmbh Wirkstoffhaltige liposome
CA2442539C (en) * 2001-03-27 2011-11-08 Phares Pharmaceutical Research N.V. Method and composition for solubilising a biologically active compound with low water solubility
US20060165766A1 (en) * 2001-09-06 2006-07-27 Yechezkel Barenholz Method for preparing liposome formulations with a predefined release profile
US9186322B2 (en) 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
CN1681478A (zh) * 2002-08-02 2005-10-12 川塞夫有限公司 铂聚集体及其制备方法
AU2003298738A1 (en) * 2002-11-26 2004-06-18 Su-Ming Chiang Liposomal formulations
AU2003303368B2 (en) * 2002-12-31 2010-06-17 Zydus Bsv Pharma Private Limited Non-pegylated long-circulating liposomes
WO2005072776A2 (en) * 2004-01-30 2005-08-11 Instytut Farmaceutyczny Liposomal formulations of the antineoplastic agents
US8241663B2 (en) 2004-03-26 2012-08-14 Terumo Kabushiki Kaisha Liposome preparation
US20060051406A1 (en) * 2004-07-23 2006-03-09 Manjeet Parmar Formulation of insoluble small molecule therapeutics in lipid-based carriers
AU2006209335A1 (en) * 2005-01-18 2006-07-27 National University Corporation Hokkaido University Method for coating particle with lipid film
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US8246984B2 (en) 2005-12-06 2012-08-21 Rigel Pharmaceuticals, Inc. Formulation of insoluble small molecule therapeutics in lipid-based carriers
WO2010034837A1 (en) * 2008-09-26 2010-04-01 Phares Pharmaceutical Research N.V. Method of solubilising biologically active compounds
CN101474155B (zh) * 2009-01-24 2011-03-16 重庆医科大学 注射用肺靶向载药前体脂质体及其使用方法
PL387296A1 (pl) * 2009-02-17 2010-08-30 Instytut Farmaceutyczny Sposób aktywnego zamykania amfifilowych substancji czynnych w strukturach liposomowych
WO2010143970A2 (en) * 2009-06-08 2010-12-16 Epitarget As Acoustically sensitive drug delivery particles comprising non-lamellar forming phosphatidylcholine
PL226015B1 (pl) 2011-03-03 2017-06-30 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna
CN115414384A (zh) 2012-09-04 2022-12-02 埃莱森制药有限责任公司 用顺铂脂质复合物预防癌症的肺部复发
RU2655964C2 (ru) 2012-11-20 2018-05-30 Спектрум Фармасьютикалз, Инк. Улучшенный способ получения инкапсулированного в липосомы винкристина для терапевтического применения
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
BR112019014718A2 (pt) 2017-01-18 2020-03-10 Temasek Life Sciences Laboratory Limited Lipossomas hiperestabilizados aumentam o direcio-namento de células mitóticas
GR20180100082A (el) * 2018-02-28 2019-09-25 ΝΙΚΟΛΑΟΣ Α. ΦΙΚΙΩΡΗΣ ΚΑΙ ΣΙΑ ΕΤΑΙΡΕΙΑ ΠΕΡΙΟΡΙΣΜΕΝΗΣ ΕΥΘΗΝΗΣ με δ.τ. IN TOUCH HEALTH Ε.Π.Ε Μεθοδος για την παραγωγη οχηματων μεταφορας λιπιδιων
EP4045054A4 (en) * 2019-10-14 2023-11-29 The Regents of the University of California NANO-ACTIVATED IMMUNOTHERAPY FOR CANCER
CN112023059B (zh) * 2020-06-03 2023-03-24 太原师范学院 一种pH响应型阿霉素无载体纳米药物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0088046B1 (de) * 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4551288A (en) * 1982-08-16 1985-11-05 Sandoz, Inc. Processes for the preparation of liposome drug delivery systems
GB8325496D0 (en) * 1983-09-23 1983-10-26 Hider R C Pharmaceutical compositions
CA1264668C (en) * 1984-06-20 1990-01-23 EXTRUSION TECHNIQUES FOR THE PRODUCTION OF LIPOSOMES
CA1270198A (en) * 1984-08-08 1990-06-12 Marcel B. Bally Encapsulation of antineoplastic agents in liposomes
US4622188A (en) * 1984-12-21 1986-11-11 E. I. Du Pont De Nemours And Company Method for manufacturing liposomes
US4737323A (en) * 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
IE60901B1 (en) * 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
CA1338702C (en) * 1987-03-05 1996-11-12 Lawrence D. Mayer High drug:lipid formulations of liposomal- antineoplastic agents

Also Published As

Publication number Publication date
DE3855265D1 (de) 1996-06-13
BR1100687A (pt) 2000-02-08
JPH02502458A (ja) 1990-08-09
AU620545B2 (en) 1992-02-20
DE3856550T2 (de) 2003-12-11
IL85608A0 (en) 1988-08-31
ATE231389T1 (de) 2003-02-15
ES2198429T3 (es) 2004-02-01
DK98189A (da) 1989-03-01
EP0290296A3 (en) 1989-06-28
HK1007500A1 (en) 1999-04-16
CA1338702C (en) 1996-11-12
GR3020725T3 (en) 1996-11-30
AU8141891A (en) 1991-10-10
AU645332B2 (en) 1994-01-13
AU1481688A (en) 1988-09-26
DK98189D0 (da) 1989-03-01
DK174869B1 (da) 2004-01-12
AU8141791A (en) 1991-11-07
DE3855265T2 (de) 1996-12-12
EP0290296A2 (en) 1988-11-09
IL85608A (en) 1992-07-15
AU635435B2 (en) 1993-03-18
KR960013703B1 (ko) 1996-10-10
DE10199004I1 (de) 2001-03-29
EP0290296B1 (en) 1996-05-08
ATE137670T1 (de) 1996-05-15
EP0719546B1 (en) 2003-01-22
KR890700340A (ko) 1989-04-24
WO1988006442A1 (en) 1988-09-07
EP0719546A1 (en) 1996-07-03
IE880599L (en) 1988-09-05
NL300036I1 (nl) 2001-03-01
IE75713B1 (en) 1997-09-24
IE960340L (en) 1988-09-05
JP2882607B2 (ja) 1999-04-12
DE3856550D1 (de) 2003-02-27
LU90717I2 (fr) 2001-03-15

Similar Documents

Publication Publication Date Title
ES2088385T3 (es) Formulaciones de liposomas con una elevada relacion agente antineoplasico/lipido.
DK86988D0 (da) Liposompraeparat og anvendelse deraf
DK434187D0 (da) Injektionspraeparat omfattende i phospholipidpartikler indkapslede antifungale polyen-antibiotika
CA1270198C (en) ENCAPSULATION OF ANTINEOPLASTIC AGENTS IN LIPOSONES
AU587232B2 (en) Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles and methods for using same for tumor therapy
PT87545A (pt) Prostaglandin-lipid formulations
GR1003711B (el) Μεθοδος δια την παρασκευη φαρμακευτικων συνθεσεων δια συστηματικην διαδερμικην χορηγησιν.
DK0580817T3 (da) Farmaceutisk præparat og fremgangsmåde til fremstilling deraf
ATE193830T1 (de) Zubereitungen enthaltend leflunomide
DK0560138T3 (da) Liposomale præparater af virksomt stof og fremgangsmåde til deres fremstilling
IT8812585A0 (it) Preparato, in particolare preparato cosmetico antisolare, nonche' metodo per l'introduzione di una sostanza attiva nella pelle
DE3851842D1 (de) Wässrige bereitung von liposomenzusammensetzungen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 290296

Country of ref document: ES

SPCD Supplementary protection certificate rejected

Free format text: MYOCET MOTIVO: SUBSISTEN DEFECTOS QUE NO HAN SIDO DEBIDAMENTE SUBSANADOS EN EL PLAZO OTORGADO.

Spc suppl protection certif: C200100008

Filing date: 20010123

Effective date: 20040907